BANK VONTOBEL/CALL/NOVO NORDISK ADR B/140/0.1/17.01.25

BANK VONTOBEL/CALL/NOVO NORDISK ADR B/140/0.1/17.01.25 Share Price

DE000VM9BZJ5

Real-time Boerse Frankfurt Warrants 09:20:25 27/06/2024 BST
1.69 ^EUR	0.00%

Current month	+48.25%
1 month	+29.01%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart BANK VONTOBEL/CALL/NOVO NORDISK ADR B/140/0.1/17.01.25

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?	02-07	PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?	02-01	PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?	01-17	PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog?	01-11	PR

More news

Quotes 5-day view

Date	Price	Change
27/06/24	1.69	0.00%
26/06/24	1.69	-9.63%
25/06/24	1.87	+19.11%
24/06/24	1.57	-0.63%
21/06/24	1.58	+2.60%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 09:20 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
WKN	VM9BZJ
ISIN	DE000VM9BZJ5
Date issued	30/01/2024
Strike	140 $
Maturity	17/01/2025 (205 Days)
Parity	10 : 1
Emission price	0.42 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	1.91 €
Lowest since issue	0.5 €
Delta	0.63x
Omega	4.983
Premium	10.03x
Gearing	7.94x
Moneyness	1.026
Difference Strike	-3.67 $
Difference Strike %	-2.62%
Spread	0.02 €
Spread %	1.18%
Theoretical value	1.690
Implied Volatility	34.14 %
Total Loss Probability	46.93 %
Intrinsic value	0.3429
Present value	1.347
Break even	158.09 €
Theta	-0.03x
Vega	0.04x
Rho	0.04x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company